

Active substances set

Search phrase: pertuzumab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant breast cancer

Pertuzumab	Early breast cancer Pertuzumab is indicated for use in combination with trastuzumab and chemotherapy in: - the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence; - the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. Metastatic breast cancer Pertuzumab is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.	REIMBURSEMENT WITH RESTRICTIONS ESMO